Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Treasury Shares (2016 - 2024)

Historic Treasury Shares for UroGen Pharma (URGN) over the last 9 years, with Q4 2024 value amounting to $1.5 million.

  • UroGen Pharma's Treasury Shares rose 3723.95% to $1.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.5 million, marking a year-over-year increase of 3723.95%. This contributed to the annual value of $1.5 million for FY2024, which is 3723.95% up from last year.
  • Latest data reveals that UroGen Pharma reported Treasury Shares of $1.5 million as of Q4 2024, which was up 3723.95% from $1.1 million recorded in Q4 2023.
  • UroGen Pharma's Treasury Shares' 5-year high stood at $1.5 million during Q4 2024, with a 5-year trough of $690955.0 in Q4 2022.
  • Its 5-year average for Treasury Shares is $954231.4, with a median of $753274.0 in 2021.
  • Per our database at Business Quant, UroGen Pharma's Treasury Shares crashed by 827.31% in 2022 and then surged by 5900.95% in 2023.
  • Over the past 5 years, UroGen Pharma's Treasury Shares (Quarter) stood at $720416.0 in 2020, then rose by 4.56% to $753274.0 in 2021, then decreased by 8.27% to $690955.0 in 2022, then skyrocketed by 59.01% to $1.1 million in 2023, then surged by 37.24% to $1.5 million in 2024.
  • Its Treasury Shares stands at $1.5 million for Q4 2024, versus $1.1 million for Q4 2023 and $690955.0 for Q4 2022.